Navigation Links
Fingerprinting prostate cancer

Two new genes which are active in prostate cancer have been identified by US researchers. At a molecular level, cancer tissue differs markedly from normal healthy tissue in its pattern of gene activity. Researchers have now developed the tools that can visualise analyse these 'molecular fingerprints' that characterise the cancerous cell. Using microarray technology, it's now possible to analyse thousands of genes in one experiments.//

Doctors at the University of Michigan have now produced the first ever molecular fingerprint of prostate cancer. They examined more than 700 prostate tissue samples from more than 50 men - covering normal tissue, tissue with benign change, and also tissues from both localised and aggressive prostate cancer. They found that more than 200 genes were expressed differently between normal and cancer tissue. Of these, some are already known to be involved in cancer, while others were completely new.

Of particular interest were two genes - hepsin and pim-1. The highest levels of hepsin were found in pre-cancerous tissue just before cancer develops, and the lowest in benign prostate tissue. Hepsin play a main role in tumour development. Pim-1, a known cancer-causing gene, was also highly expressed in prostate cancer tissue. Levels of hepsin and Pim-1 were significantly linked to prognosis, when the men's clinical histories were checked.

The researchers say that the discovery of prostate cancer's molecular fingerprint could lead to many new diagnostic tests. These could offer more to the patient than the current PSA (prostate specific antigen) test and can be used as a useful diagnostic tool.


'"/>




Page: 1

Related medicine news :

1. Better prostate cancer detection
2. Protective effects of tomatoes in prostate cancer
3. Early detection of prostate cancer
4. No link between blood groups and prostate cancer
5. Cure for osteoporosis in prostate cancer patients
6. Novel biopsy technique for prostate cancer
7. New diagnostic marker for prostate cancer
8. Inadequate proof to justify routine prostate screen
9. Combination regime may work against prostate cancer
10. Lifestyle linked to prostate cancer risk
11. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: